HOPE Therapeutics Expands Mental Health Care Footprint with Acquisition of Kadima Neuropsychiatry Institute

HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals (NASDAQ: NRXP), has announced the acquisition of Kadima Neuropsychiatry Institute in La Jolla, California, a move poised to significantly expand its presence in the mental health care sector. This acquisition is not only expected to be accretive to both revenue and EBITDA but also positions Kadima as the clinical model for HOPE's ambitious plan to establish a nationwide network of psychiatric clinics. By the end of 2025, HOPE aims to acquire 30 clinics, projecting an annual revenue of $100 million.

Dr. David Feifel, the founder and medical director of Kadima, will join HOPE as Chief Medical Innovation Officer, bringing his expertise in interventional psychiatry to the forefront of the company's expansion efforts. Kadima is renowned for its integration of clinical care with cutting-edge research into treatments such as psychedelic medications and transcranial magnetic stimulation (TMS), offering hope for patients with conditions like suicidal depression and PTSD.

The acquisition underscores the growing importance of innovative treatments in mental health care and the potential economic impact of the cannabis and psychedelic industries. With NRx Pharmaceuticals' pipeline including investigational drugs for suicidal bipolar depression and chronic pain, the collaboration between HOPE and Kadima could pave the way for groundbreaking advancements in psychiatric treatment. For more details on the acquisition, visit https://ibn.fm/uwHMj.